| Literature DB >> 34031962 |
Li Li1,2, Pierre Galichon1,2, Xiaoyan Xiao1, Ana C Figueroa-Ramirez1, Diana Tamayo1, Jake J-K Lee3, Marian Kalocsay4,5, David Gonzalez-Sanchez1, Maria S Chancay1, Kyle W McCracken1,2, Nathan N Lee1, Takaharu Ichimura1,2, Yutaro Mori1, M Todd Valerius1,2,6, Julia Wilflingseder1, Dario R Lemos1,2, Elazer R Edelman2,7,8, Joseph V Bonventre1,2,4,6.
Abstract
Recent studies demonstrate that metabolic disturbance, such as augmented glycolysis, contributes to fibrosis. The molecular regulation of this metabolic perturbation in fibrosis, however, has been elusive. COUP-TFII (also known as NR2F2) is an important regulator of glucose and lipid metabolism. Its contribution to organ fibrosis is undefined. Here, we found increased COUP-TFII expression in myofibroblasts in human fibrotic kidneys, lungs, kidney organoids, and mouse kidneys after injury. Genetic ablation of COUP-TFII in mice resulted in attenuation of injury-induced kidney fibrosis. A non-biased proteomic study revealed the suppression of fatty acid oxidation and the enhancement of glycolysis pathways in COUP-TFII overexpressing fibroblasts. Overexpression of COUP-TFII in fibroblasts also induced production of alpha-smooth muscle actin (αSMA) and collagen 1. Knockout of COUP-TFII decreased glycolysis and collagen 1 levels in fibroblasts. Chip-qPCR revealed the binding of COUP-TFII on the promoter of PGC1α. Overexpression of COUP-TFII reduced the cellular level of PGC1α. Targeting COUP-TFII serves as a novel treatment approach for mitigating fibrosis in chronic kidney disease and potentially fibrosis in other organs.Entities:
Keywords: COUP-TFII; TGFβ; acute kidney injury; fibrosis; glycolysis
Mesh:
Substances:
Year: 2021 PMID: 34031962 PMCID: PMC8183413 DOI: 10.15252/embr.202051169
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 9.071